Sildenafil Citrate Tablet
Product Images NDC 50090-3905

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Sildenafil Citrate (NDC 50090-3905). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

2 (55aa9711 6df5 4516 Bf00 A1acf7f7a464 01)

This text appears to be a graph of the "Estimated Cumulative Mortality Rate (%)" over time, with various doses labeled on the y-axis. The x-axis corresponds with time in years. However, the graph appears incomplete as there are missing values and labels.*

FDA Label Image

1 (55aa9711 6df5 4516 Bf00 A1acf7f7a464 02)

FDA Label Image

7 (55aa9711 6df5 4516 Bf00 A1acf7f7a464 03)

This is information related to drug interactions with Sildenafil. The document lists various drugs and their recommended dose adjustments when administered with Sildenafil. For example, drugs like Atorvastatin, Adithromyein, and Mes do not require any dose adjustment. On the other hand, drugs like Cimetidine and Saquinavir require some dose adjustment when co-administered with Sildenafil. However, the document mentions that the addition of Sildenafil to Bosentan therapy does not benefit exercise capacity based on clinical studies. Additionally, there is a graph depicting changes in fold relative to Sildenafil alone, with a solid line at x=1.*

FDA Label Image

8 (55aa9711 6df5 4516 Bf00 A1acf7f7a464 04)

This text is an interaction table of a drug called Acenocoumarol with other drugs. It shows the effect of interaction on INR AUC, INR Cmax, Auc, Cmax, and the fold change and 80% CI. The table also provides recommendations on whether or not to adjust the dose and if co-administration is recommendable for each drug. The text also includes a note on the effect of Flonavir on Sildenafil and a clinical study on the effect of Sidonati added to Bosantan therapy on exercise capacity.*

FDA Label Image

4 (55aa9711 6df5 4516 Bf00 A1acf7f7a464 05)

This is a table showing the change from the baseline in meters for different dosages (Placebo, Sildenafil at 20mg TID, Sildenafil at 40mg TID, and Sildenafil at 80mg TID) of a drug at different intervals of the study (Week 4, Week 8, and Week 12).*

FDA Label Image

5 (55aa9711 6df5 4516 Bf00 A1acf7f7a464 06)

This is a medical document showing the results of a clinical trial involving a placebo and a drug called Sildenafil. The document lists study participants and their characteristics such as age, gender, and mean pulmonary arterial pressure (PAP) measured in millimeters of mercury (mmHg). The document also includes measurements of the baseline walk distance and the change in six-minute walk distance after taking the drug or placebo.*

FDA Label Image

1 (55aa9711 6df5 4516 Bf00 A1acf7f7a464 07)

FDA Label Image

Figure 12 (55aa9711 6df5 4516 Bf00 A1acf7f7a464 08)

The provided text is a figure with a plot showing the mean change in six minutes walk measured in meters from baseline by visit up to week 12 for the ITT population in a study using the Sildenafil Protocol A1481244. The plot provides information on the change from baseline in meters along with error bars for each treatment (Sildenafil 1mg TID, Sildenafil 5mg TID, and Sildenafil 20mg TID) at Week 4, Week 8, and Week 12.*

FDA Label Image

9 (55aa9711 6df5 4516 Bf00 A1acf7f7a464 09)

FDA Label Image

9 (55aa9711 6df5 4516 Bf00 A1acf7f7a464 10)

FDA Label Image

Label Image (Lbl500903905)

This is a description of a medication with product number 6604-0. The medication contains 20mg of sildenafil citrate and comes in a box of 30 tablets.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.